There are multiple CD4/CD6 inhibitors that are currently available for metastatic estrogen receptor-positive breast cancers, including Ibrance, Kisqali, and Verzenio. When you hear estrogen receptor-positive breast cancer that means it is one that needs estrogen to grow. CD4/CD6 drugs are meant to interrupt the growth of cancer cells by decreasing the amount of estrogen cancer cells can get. The different CD4/CD6 options, however, do come with different side effects. Dr. Elizabeth Comen, a medical oncologist at Memorial Sloan Kettering Cancer Center and an advisor to SurvivorNet, said while these drugs are generally really well-tolerated — it’s still important to have a conversation with your doctor about what the potential side effects are.
“They each have a slightly different side effect profile and it’s really important to talk to your doctor about what those side effects are, and what drug may be right for you,” Dr. Comen said.
Read MoreLearn more about SurvivorNet's rigorous medical review process.